Latest Articles
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO - Citeline News & Insights
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO Citeline News & Insights
Published: Oct. 20, 2025, 10:35 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 20, 2025, 9:33 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com
Published: Oct. 20, 2025, 3:02 p.m.
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU - The Manila Times
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU The Manila Times
Published: Oct. 20, 2025, 12:36 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire
Published: Oct. 20, 2025, noon
Could this lakeside mansion set a new Ballarat price record? - Herald Sun
Could this lakeside mansion set a new Ballarat price record? Herald Sun
Published: Oct. 20, 2025, 4:53 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - BioSpace
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer BioSpace
Published: Oct. 20, 2025, 4:42 a.m.
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region - Cureus
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region Cureus
Published: Oct. 19, 2025, 12:43 a.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti - PharmiWeb.com
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti PharmiWeb.com
Published: Oct. 18, 2025, 1:03 p.m.
Link copied to clipboard!